SOPH Insider Trading Activity and SEC Form 4 Filings
SOPH insider trading summary
Over the past 12 months, insiders at SOPHiA GENETICS SA (SOPH) reported 139 sales worth $5.0M by 10 insiders and no open-market purchases on SEC Form 4. Net insider selling was $5.0M.
Latest SOPH insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Oct 13, 2026 | Zhenyu Xu | Chief Scientific Officer | Sell | $29K (4,000 @ $7.18) |
| Oct 12, 2026 | Philippe Menu | Chief Medical Officer | Sell | $36K (5,000 @ $7.26) |
| Oct 12, 2026 | Jurgi Camblong | Executive Chairman | Sell | $62K (8,500 @ $7.26) |
| Oct 5, 2026 | Well Daan Van | Chief Legal Officer | Sell | $50K (6,168 @ $8.12) |
| Oct 5, 2026 | George Cardoza | Chief Financial Officer | Sell | $13K (1,592 @ $8.10) |
| Oct 5, 2026 | Zhenyu Xu | Chief Scientific Officer | Sell | $60K (7,394 @ $8.12) |
| Oct 5, 2026 | Kevin Puylaert | Chief Sales Officer | Sell | $246 (31 @ $7.92) |
| Oct 5, 2026 | Jurgi Camblong | Executive Chairman | Sell | $327K (40,172 @ $8.13) |
| Oct 5, 2026 | Kevin Puylaert | Chief Sales Officer | Sell | $1K (185 @ $8.06) |
| Oct 5, 2026 | Ross Muken | Chief Executive Officer | Sell | $80K (9,838 @ $8.13) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.